- KT and NeuroSigma partner to jointly develop and commercialize neuroelectronic ADHD therapies inside and outside of Korea
- Partnership will expand to include digital therapy services for the treatment of other neuropsychiatric disorders such as depression and epilepsy
- KT and NeuroSigma will work together to commercialize and establish manufacturing of products in Korea as part of the KT digital healthcare platform
PR Newswire
SEOUL, South Korea and LOS ANGELES, June 14, 2021